AxoGen (NASDAQ:AXGN – Get Free Report) is anticipated to announce its Q3 2026 results before the market opens on Wednesday, October 28th. Analysts expect AxoGen to announce earnings of $0.1313 per share and revenue of $73.18 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, October 28, 2026 at 8:00 AM ET.
AxoGen (NASDAQ:AXGN – Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.12. AxoGen had a negative return on equity of 8.90% and a negative net margin of 13.36%. The business had revenue of $69.73 million for the quarter, compared to analyst estimates of $67.10 million. On average, analysts expect AxoGen to post ($0.44) EPS for the current fiscal year and $0.09 EPS for the next fiscal year.
AxoGen Price Performance
Shares of AXGN opened at $38.26 on Tuesday. The stock has a market cap of $2.06 billion, a P/E ratio of -56.29 and a beta of 1.17. The business’s fifty day moving average is $43.04 and its 200 day moving average is $39.18. AxoGen has a 12-month low of $17.14 and a 12-month high of $52.91. The company has a quick ratio of 5.04, a current ratio of 6.60 and a debt-to-equity ratio of 0.07.
Analyst Upgrades and Downgrades
A number of analysts have commented on the company. Morgan Stanley lowered AxoGen to a “hold” rating in a report on Tuesday, September 29th. Truist Financial reduced their target price on shares of AxoGen from $60.00 to $53.00 and set a “buy” rating for the company in a research report on Thursday, October 1st. Bank of America initiated coverage on shares of AxoGen in a research note on Monday, October 12th. They issued a “buy” rating and a $52.00 target price for the company. Wall Street Zen lowered AxoGen from a “buy” rating to a “hold” rating in a research note on Saturday, September 26th. Finally, Canaccord Genuity Group increased their target price on shares of AxoGen from $50.00 to $55.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Twelve research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, AxoGen currently has a consensus rating of “Moderate Buy” and an average target price of $51.27.
View Our Latest Research Report on AXGN
Insider Buying and Selling
In related news, Director Joseph A. Tyndall sold 3,500 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $49.70, for a total transaction of $173,950.00. Following the transaction, the director owned 10,650 shares in the company, valued at $529,305. The trade was a 24.73% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathy Weiler sold 14,150 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $45.30, for a total value of $640,995.00. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 98,503 shares of company stock worth $4,656,947. 2.44% of the stock is owned by company insiders.
AxoGen Company Profile
AxoGen, Inc (NASDAQ: AXGN) is a medical technology company focused on developing and commercializing products for the repair and regeneration of peripheral nerves. Its technologies are designed to help restore sensory and motor function following traumatic injuries, surgical procedures, and other conditions affecting peripheral nerves.
The company’s product portfolio includes Avance Nerve Graft, a processed human nerve allograft used to bridge gaps in damaged nerves without requiring tissue to be taken from another part of the patient’s body.
Featured Stories
- Five stocks we like better than AxoGen
- Intel’s $155 Price Target Raises a Bigger Question About Its Turnaround Potential
- AST SpaceMobile Faces Launch Risks as SpaceX Raises the Competitive Stakes
- GXO Logistics Is Turning Warehouse Robots Into a Growth Strategy
- A Solid Margin Story Means the Sell-Off in DECK May Be Overdone
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.
